HC Wainwright Analysts Reduce Earnings Estimates for ANRO

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at HC Wainwright reduced their Q2 2025 earnings estimates for Alto Neuroscience in a research note issued to investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.15) EPS, FY2028 earnings at ($3.06) EPS and FY2029 earnings at ($1.72) EPS.

A number of other equities research analysts also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $15.40.

Alto Neuroscience Stock Down 1.4%

ANRO opened at $2.87 on Thursday. The firm has a market capitalization of $77.70 million, a P/E ratio of -1.23 and a beta of 1.87. Alto Neuroscience has a one year low of $1.60 and a one year high of $17.55. The company has a fifty day moving average price of $2.34 and a 200-day moving average price of $3.41. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.06.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after acquiring an additional 3,139 shares during the last quarter. Deutsche Bank AG increased its position in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience during the 4th quarter valued at about $74,000. Jane Street Group LLC raised its holdings in shares of Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Alto Neuroscience in the 1st quarter worth approximately $52,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.